Skip to main content
Erschienen in: International Journal of Hematology 4/2009

01.11.2009 | Original Article

Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan

verfasst von: Tomohiro Morio, Naomi Takahashi, Fumiaki Watanabe, Fumiko Honda, Masaki Sato, Masatoshi Takagi, Ken-ichi Imadome, Toshio Miyawaki, Domenico Delia, Kotoka Nakamura, Richard A. Gatti, Shuki Mizutani

Erschienen in: International Journal of Hematology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

A nationwide survey was conducted for identifying ataxia-telangiectasia (AT) patients in Japan. Eighty-nine patients were diagnosed between 1971 and 2006. Detailed clinical and laboratory data of 64 patients including affected siblings were collected. Analyses focused on malignancy, therapy-related toxicity, infection, and hematological/immunological parameters. The phenotypic variability of AT was assessed by comparing 26 affected siblings from 13 families. Malignancy developed in 22% of the cases and was associated with a high rate of severe therapy-related complications: chemotherapy-related cardiac toxicity in 2 children, and severe hemorrhagic cystitis requiring surgery in 2 patients. The frequency of serious viral infections correlated with the T cell count. Hypogammaglobulinemia with hyper-IgM (HIGM) was recorded in 5 patients, and 3 patients developed panhypogammaglobulinemia. Differences in immunological parameters were noted in siblings. Four patients showed an HIGM phenotype, in contrast to their siblings with normal IgG and IgM levels. The patients with HIGM phenotype showed reduced levels of TRECs and CD27+CD20+ memory B cells. The findings suggest that hitherto unidentified modifier genes or exogenous environmental factors can influence the overall immune responses. Our data along with future prospective study will lead to better understanding of the hematological/immunological phenotypes and to better care of the patients.
Literatur
1.
Zurück zum Zitat Claret Teruel G, Giner Munoz MT, Plaza Martin AM, Martin Mateos MA, Piquer Gibert M, Sierra Martinez JI. Variability of immunodeficiency associated with ataxia telangiectasia and clinical evolution in 12 affected patients. Pediatr Allergy Immunol. 2005;16:615–8.CrossRefPubMed Claret Teruel G, Giner Munoz MT, Plaza Martin AM, Martin Mateos MA, Piquer Gibert M, Sierra Martinez JI. Variability of immunodeficiency associated with ataxia telangiectasia and clinical evolution in 12 affected patients. Pediatr Allergy Immunol. 2005;16:615–8.CrossRefPubMed
2.
Zurück zum Zitat Gatti RA. Ataxia-telangiectasia. In: Scriver CR, Beaudet AL, Sly WS, editors. Metabolic and molecular basis of inherited diseases. New York: Mcgraw-Hill; 2001. p. 1187–96. Gatti RA. Ataxia-telangiectasia. In: Scriver CR, Beaudet AL, Sly WS, editors. Metabolic and molecular basis of inherited diseases. New York: Mcgraw-Hill; 2001. p. 1187–96.
3.
Zurück zum Zitat Gatti RA, Becker-Catania S, Chun HH, Sun X, Mitui M, Lai CH, et al. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001;20:87–108.CrossRefPubMed Gatti RA, Becker-Catania S, Chun HH, Sun X, Mitui M, Lai CH, et al. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol. 2001;20:87–108.CrossRefPubMed
4.
Zurück zum Zitat Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003;10:173–82.CrossRefPubMed Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003;10:173–82.CrossRefPubMed
5.
Zurück zum Zitat Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998;102:98–100.CrossRefPubMed Cabana MD, Crawford TO, Winkelstein JA, Christensen JR, Lederman HM. Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics. 1998;102:98–100.CrossRefPubMed
6.
Zurück zum Zitat Moin M, Aghamohammadi A, Kouhi A, Tavassoli S, Rezaei N, Ghaffari SR, et al. Ataxia-telangiectasia in Iran: clinical and laboratory features of 104 patients. Pediatr Neurol. 2007;37:21–8.CrossRefPubMed Moin M, Aghamohammadi A, Kouhi A, Tavassoli S, Rezaei N, Ghaffari SR, et al. Ataxia-telangiectasia in Iran: clinical and laboratory features of 104 patients. Pediatr Neurol. 2007;37:21–8.CrossRefPubMed
7.
8.
Zurück zum Zitat Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505–11.CrossRefPubMed Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505–11.CrossRefPubMed
9.
Zurück zum Zitat Vacchio MS, Olaru A, Livak F, Hodes RJ. ATM deficiency impairs thymocyte maturation because of defective resolution of T cell receptor alpha locus coding end breaks. Proc Natl Acad Sci USA. 2007;104:6323–8.CrossRefPubMedPubMedCentral Vacchio MS, Olaru A, Livak F, Hodes RJ. ATM deficiency impairs thymocyte maturation because of defective resolution of T cell receptor alpha locus coding end breaks. Proc Natl Acad Sci USA. 2007;104:6323–8.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53.CrossRefPubMed Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–53.CrossRefPubMed
11.
Zurück zum Zitat Lange E, Borresen AL, Chen X, Chessa L, Chiplunkar S, Concannon P, et al. Localization of an ataxia-telangiectasia gene to an approximately 500-kb interval on chromosome 11q23.1: linkage analysis of 176 families by an international consortium. Am J Hum Genet. 1995;57:112–9.PubMedPubMedCentral Lange E, Borresen AL, Chen X, Chessa L, Chiplunkar S, Concannon P, et al. Localization of an ataxia-telangiectasia gene to an approximately 500-kb interval on chromosome 11q23.1: linkage analysis of 176 families by an international consortium. Am J Hum Genet. 1995;57:112–9.PubMedPubMedCentral
13.
Zurück zum Zitat Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155–68.CrossRefPubMed Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155–68.CrossRefPubMed
14.
Zurück zum Zitat Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci. 2006;31:402–10.CrossRefPubMed Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci. 2006;31:402–10.CrossRefPubMed
15.
Zurück zum Zitat Reliene R, Schiestl RH. Antioxidants suppress lymphoma and increase longevity in ATM-deficient mice. J Nutr. 2007;137:229S–32S.CrossRefPubMed Reliene R, Schiestl RH. Antioxidants suppress lymphoma and increase longevity in ATM-deficient mice. J Nutr. 2007;137:229S–32S.CrossRefPubMed
16.
Zurück zum Zitat Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst). 2006;5:852–9.CrossRef Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst). 2006;5:852–9.CrossRef
17.
Zurück zum Zitat Du L, Pollard JM, Gatti RA. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci USA. 2007;104:6007–12.CrossRefPubMedPubMedCentral Du L, Pollard JM, Gatti RA. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc Natl Acad Sci USA. 2007;104:6007–12.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA. 2004;101:15676–81.CrossRefPubMedPubMedCentral Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA. 2004;101:15676–81.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K, et al. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood. 2003;101:3622–7.CrossRefPubMed Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K, et al. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood. 2003;101:3622–7.CrossRefPubMed
20.
Zurück zum Zitat Takagi M, Tsuchida R, Oguchi K, Shigeta T, Nakada S, Shimizu K, et al. Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease. Blood. 2004;103:283–90.CrossRefPubMed Takagi M, Tsuchida R, Oguchi K, Shigeta T, Nakada S, Shimizu K, et al. Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease. Blood. 2004;103:283–90.CrossRefPubMed
21.
Zurück zum Zitat Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Piane M, et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet. 1998;62:551–61.CrossRefPubMedPubMedCentral Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Piane M, et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. Am J Hum Genet. 1998;62:551–61.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Birrell GW, Kneebone K, Nefedov M, Nefedova E, Jartsev MN, Mitsui M, et al. ATM mutations, haplotype analysis, and immunological status of Russian patients with ataxia telangiectasia. Hum Mutat. 2005;25:593.CrossRefPubMed Birrell GW, Kneebone K, Nefedov M, Nefedova E, Jartsev MN, Mitsui M, et al. ATM mutations, haplotype analysis, and immunological status of Russian patients with ataxia telangiectasia. Hum Mutat. 2005;25:593.CrossRefPubMed
24.
Zurück zum Zitat Morio T, Hanissian SH, Bacharier LB, Teraoka H, Nonoyama S, Seki M, et al. Ku in the cytoplasm associates with CD40 in human B cells and translocates into the nucleus following incubation with IL-4 and anti-CD40 mAb. Immunity. 1999;11:339–48.CrossRefPubMed Morio T, Hanissian SH, Bacharier LB, Teraoka H, Nonoyama S, Seki M, et al. Ku in the cytoplasm associates with CD40 in human B cells and translocates into the nucleus following incubation with IL-4 and anti-CD40 mAb. Immunity. 1999;11:339–48.CrossRefPubMed
25.
Zurück zum Zitat Morio T, Nagasawa M, Nonoyama S, Okawa H, Yata J. Phenotypic profile and functions of T cell receptor-gamma delta-bearing cells from patients with primary immunodeficiency syndrome. J Immunol. 1990;144:1270–5.PubMed Morio T, Nagasawa M, Nonoyama S, Okawa H, Yata J. Phenotypic profile and functions of T cell receptor-gamma delta-bearing cells from patients with primary immunodeficiency syndrome. J Immunol. 1990;144:1270–5.PubMed
26.
Zurück zum Zitat Al-Harthi L, Marchetti G, Steffens CM, Poulin J, Sekaly R, Landay A. Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). J Immunol Methods. 2000;237:187–97.CrossRefPubMed Al-Harthi L, Marchetti G, Steffens CM, Poulin J, Sekaly R, Landay A. Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). J Immunol Methods. 2000;237:187–97.CrossRefPubMed
27.
Zurück zum Zitat Suzuki K, Tsugawa K, Oki E, Morio T, Ito E, Tanaka H, et al. Vesical varices and telangiectasias in a patient with ataxia telangiectasia. Pediatric Nephrology. 2008;23:1005–8.CrossRefPubMed Suzuki K, Tsugawa K, Oki E, Morio T, Ito E, Tanaka H, et al. Vesical varices and telangiectasias in a patient with ataxia telangiectasia. Pediatric Nephrology. 2008;23:1005–8.CrossRefPubMed
28.
Zurück zum Zitat Giovannetti A, Mazzetta F, Caprini E, Aiuti A, Marziali M, Pierdominici M, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood. 2002;100:4082–9.CrossRefPubMed Giovannetti A, Mazzetta F, Caprini E, Aiuti A, Marziali M, Pierdominici M, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood. 2002;100:4082–9.CrossRefPubMed
29.
Zurück zum Zitat Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst). 2004;3:1187–96.CrossRef Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst). 2004;3:1187–96.CrossRef
30.
Zurück zum Zitat Marshall FF, Klinefelter HF. Late hemorrhagic cystitis following low-dose cyclophosphamide therapy. Urology. 1979;14:573–5.CrossRefPubMed Marshall FF, Klinefelter HF. Late hemorrhagic cystitis following low-dose cyclophosphamide therapy. Urology. 1979;14:573–5.CrossRefPubMed
31.
Zurück zum Zitat Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer. 1988;61:451–7.CrossRefPubMed Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer. 1988;61:451–7.CrossRefPubMed
33.
Zurück zum Zitat Mizutani S. Genetic background as a possible determinant of clinical and biological features of Epstein-Barr virus infection—a hypothetical view. Crit Rev Oncol Hematol. 2002;44:217–25.CrossRefPubMed Mizutani S. Genetic background as a possible determinant of clinical and biological features of Epstein-Barr virus infection—a hypothetical view. Crit Rev Oncol Hematol. 2002;44:217–25.CrossRefPubMed
34.
Zurück zum Zitat Pan Q, Petit-Frere C, Lahdesmaki A, Gregorek H, Chrzanowska KH, Hammarstrom L. Alternative end joining during switch recombination in patients with ataxia-telangiectasia. Eur J Immunol. 2002;32:1300–8.CrossRefPubMed Pan Q, Petit-Frere C, Lahdesmaki A, Gregorek H, Chrzanowska KH, Hammarstrom L. Alternative end joining during switch recombination in patients with ataxia-telangiectasia. Eur J Immunol. 2002;32:1300–8.CrossRefPubMed
35.
Zurück zum Zitat Pan-Hammarstrom Q, Dai S, Zhao Y, van Dijk-Hard IF, Gatti RA, Borresen-Dale AL, et al. ATM is not required in somatic hypermutation of VH, but is involved in the introduction of mutations in the switch mu region. J Immunol. 2003;170:3707–16.CrossRefPubMed Pan-Hammarstrom Q, Dai S, Zhao Y, van Dijk-Hard IF, Gatti RA, Borresen-Dale AL, et al. ATM is not required in somatic hypermutation of VH, but is involved in the introduction of mutations in the switch mu region. J Immunol. 2003;170:3707–16.CrossRefPubMed
36.
Zurück zum Zitat Pan-Hammarstrom Q, Lahdesmaki A, Zhao Y, Du L, Zhao Z, Wen S, et al. Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation. J Exp Med. 2006;203:99–110.CrossRefPubMedPubMedCentral Pan-Hammarstrom Q, Lahdesmaki A, Zhao Y, Du L, Zhao Z, Wen S, et al. Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation. J Exp Med. 2006;203:99–110.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Peron S, Pan-Hammarstrom Q, Imai K, Du L, Taubenheim N, Sanal O, et al. A primary immunodeficiency characterized by defective immunoglobulin class switch recombination and impaired DNA repair. J Exp Med. 2007;204:1207–16.CrossRefPubMedPubMedCentral Peron S, Pan-Hammarstrom Q, Imai K, Du L, Taubenheim N, Sanal O, et al. A primary immunodeficiency characterized by defective immunoglobulin class switch recombination and impaired DNA repair. J Exp Med. 2007;204:1207–16.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Reina-San-Martin B, Chen J, Nussenzweig A, Nussenzweig MC. Enhanced intra-switch region recombination during immunoglobulin class switch recombination in 53BP1−/− B cells. Eur J Immunol. 2007;37:235–9.CrossRefPubMed Reina-San-Martin B, Chen J, Nussenzweig A, Nussenzweig MC. Enhanced intra-switch region recombination during immunoglobulin class switch recombination in 53BP1−/− B cells. Eur J Immunol. 2007;37:235–9.CrossRefPubMed
39.
Zurück zum Zitat Soresina A, Meini A, Lougaris V, Cattaneo G, Pellegrino S, Piane M, et al. Different clinical and immunological presentation of ataxia-telangiectasia within the same family. Neuropediatrics. 2008;39:43–5.CrossRefPubMed Soresina A, Meini A, Lougaris V, Cattaneo G, Pellegrino S, Piane M, et al. Different clinical and immunological presentation of ataxia-telangiectasia within the same family. Neuropediatrics. 2008;39:43–5.CrossRefPubMed
Metadaten
Titel
Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan
verfasst von
Tomohiro Morio
Naomi Takahashi
Fumiaki Watanabe
Fumiko Honda
Masaki Sato
Masatoshi Takagi
Ken-ichi Imadome
Toshio Miyawaki
Domenico Delia
Kotoka Nakamura
Richard A. Gatti
Shuki Mizutani
Publikationsdatum
01.11.2009
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 4/2009
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0408-0

Weitere Artikel der Ausgabe 4/2009

International Journal of Hematology 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.